SAGE- will come back?SAGE- will come back?
-Doji candles at support.
-Key level.
-Demand zone.
-ABCD pattern.
-Fibo golden zone.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.58 USD
−541.49 M USD
86.45 M USD
49.42 M
About Sage Therapeutics, Inc.
Sector
CEO
Barry E. Greene
Headquarters
Cambridge
Website
Founded
2010
FIGI
BBG0025X16Y5
SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.
$SAGE: strong base, upcoming catalysts$SAGE is an interesting stock here, has pending catalysts for mid 2023, which fit the expectations from the Time@Mode technical pattern at hand here.
Consider the volatility of these biotech names when entering, stock could move huge after data comes out (up or down) but odds are good that it break
SAGE - longBig volume, end of the day Sep 17 shows that nstitutionals are buying.
There is a reason: SAGE receives Fast Track Designation for SAGE-718 for the Treatment of Huntington’s Disease
Technically looks strong: cap and handle pattern is bullish
Sage Therapeutics Receives Fast Track Designation for SAGE-718 fSAGE: Sage Therapeutics, Inc.
2021-09-15 06:30:00
Sage Therapeutics Receives Fast Track Designation for SAGE-718 for the Treatment of Huntington’s Disease
SAGE 62% PoP Bearish Iron Condor after event
My favorite bearish neutral trade for today.
Losing only upside, I like the extreme high IVR values to play.
Reasons to play this:
1/ After event, big selloff, high implied volatility.
2/ Extreme High Implied Volatility, good for credit strategies
3/ I can boost my original bearish vertical spread
$SAGE - obliterated earnings and dumped Could be a nice one to pick up on discount
Golden cross potential, no rush, wait for the trade to come to you
Looking to hold 80 then 82
$SAGE bullish RSI divergence The price seems to change it local downtrent direction to uptrand. We are going to 100$
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of SAGE is 4.85 USD — it has decreased by −1.22% in the past 24 hours. Watch Sage Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Sage Therapeutics, Inc. stocks are traded under the ticker SAGE.
SAGE stock has fallen by −17.38% compared to the previous week, the month change is a −37.82% fall, over the last year Sage Therapeutics, Inc. has showed a −75.26% decrease.
We've gathered analysts' opinions on Sage Therapeutics, Inc. future price: according to them, SAGE price has a max estimate of 26.00 USD and a min estimate of 4.00 USD. Watch SAGE chart and read a more detailed Sage Therapeutics, Inc. stock forecast: see what analysts think of Sage Therapeutics, Inc. and suggest that you do with its stocks.
SAGE reached its all-time high on Jan 31, 2018 with the price of 195.97 USD, and its all-time low was 5.03 USD and was reached on Nov 15, 2024. View more price dynamics on SAGE chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
SAGE stock is 8.13% volatile and has beta coefficient of 2.42. Track Sage Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Sage Therapeutics, Inc. there?
Today Sage Therapeutics, Inc. has the market capitalization of 296.69 M, it has decreased by −8.57% over the last week.
Yes, you can track Sage Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Sage Therapeutics, Inc. is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
SAGE earnings for the last quarter are −1.53 USD per share, whereas the estimation was −1.54 USD resulting in a 0.80% surprise. The estimated earnings for the next quarter are −1.53 USD per share. See more details about Sage Therapeutics, Inc. earnings.
Sage Therapeutics, Inc. revenue for the last quarter amounts to 11.87 M USD, despite the estimated figure of 10.80 M USD. In the next quarter, revenue is expected to reach 14.12 M USD.
SAGE net income for the last quarter is −93.55 M USD, while the quarter before that showed −102.85 M USD of net income which accounts for 9.04% change. Track more Sage Therapeutics, Inc. financial stats to get the full picture.
No, SAGE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 22, 2024, the company has 487.00 employees. See our rating of the largest employees — is Sage Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Sage Therapeutics, Inc. EBITDA is −370.56 M USD, and current EBITDA margin is −630.47%. See more stats in Sage Therapeutics, Inc. financial statements.
Like other stocks, SAGE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sage Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Sage Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Sage Therapeutics, Inc. stock shows the strong sell signal. See more of Sage Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.